Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

GP IIb/IIIa Inhibitors for STEMI: Still the Gold Standard or an Old Survivor?

Author(s): Giuseppe Musumeci, Matteo Baroni and Roberta Rossini

Volume 10 , Issue 4 , 2012

Page: [443 - 447] Pages: 5

DOI: 10.2174/157016112800812737

Price: $65

Abstract

Glycoprotein (GP) IIb\IIIa receptor plays a central role on platelets activation and its blockage has been a matter of interest since the beginning of percutaneous revascularization. After first promising trials, GP IIb\IIIa inhibitors (GPI) have been widely used in cath labs for about a decade, significantly improving prognosis for patients with STSegment Elevation Myocardial Infarction (STEMI). However, their utilization isn’t exempt from risks, mainly in form of bleeding disorders, which can negatively affect patients’ outcome. Moreover, routinary administration of thyenopiridines like clopidogrel and the introduction of new anticoagulants like bivalirudin significantly reduced indications for GPI. In this review, a risk/benefit evaluation GP IIb\IIIa inhibitors is presented and their indications for STEMI patients addressed to revascularization are discussed according to recent advances reported in literature.

Keywords: STEMI, glycoprotein IIb\IIIa, abcximab, eptifibatide, tirofiban, clopidogrel, bivalirudin, anticoagulants, bleeding disorders


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy